ProMIS Neurosciences完成PRECISE-AD 1b期临床试验中144例患者的入组，评估用于治疗AD的治疗性候选抗体PMN 310

Large, well-powered Phase 1b study, designed to generate clinically and biologically meaningful insights in early Alzheimer's disease

Clear and near-term value inflection points, with blinded 6-month interim data expected in Q2 2026 and final unblinded top-line results anticipated in Q4 2026

Cambridge, Massachusetts, Dec. 18, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (NASDAQ:PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson's disease (PD), today announced completion of enrollment of 144 patients in its PRECISE-AD Phase 1b clinical trial, evaluating PMN310, the Company's lead therapeutic antibody candidate for the treatment of AD.

PRECISE-AD is a randomized, double-blind, placebo-controlled study in patients with mild cognitive impairment or early AD. The 12-month trial was designed to assess the safety, tolerability, pharmacokinetics, biomarker and clinical effects of PMN310, an antibody designed to be uniquely selective for toxic soluble amyloid-beta oligomers, widely believed to be the primary drivers of synaptic dysfunction and neurodegeneration in AD.

To date, PMN310 has demonstrated a favorable safety profile, with limited patient discontinuations and no treatment-related serious adverse events (SAEs) reported during the trial.

The Company remains on track to conduct a blinded 6-month interim analysis in Q2 2026, including an evaluation of key plasma and cerebrospinal fluid biomarkers, followed by final unblinded 12-month top-line analysis expected in Q4 2026.